How should rheumatoid arthritis be treated in a patient with an active gastric ulcer?

Treatment of Rheumatoid Arthritis with Active Gastric Ulcer

In patients with rheumatoid arthritis and active gastric ulcer, avoid methotrexate and NSAIDs, initiate sulfasalazine or leflunomide as the first-line DMARD along with proton pump inhibitor therapy for ulcer healing, and continue aggressive RA treatment without delay. 1

Initial Management Strategy

Immediate Actions

• Discontinue NSAIDs immediately if currently in use, as they are a primary cause of gastric ulceration in RA patients and will prevent ulcer healing 2, 3
• Avoid methotrexate as the first-line agent due to contraindications with active gastric ulcer (MTX is contraindicated in hepatic disease and has significant GI toxicity) 1
• Start proton pump inhibitor therapy (omeprazole 20 mg daily or equivalent) for ulcer healing - this has shown 87-90% healing rates even when continuing disease-modifying therapy 2, 4

DMARD Selection

First-line options when MTX is contraindicated:

• Sulfasalazine 3-4 g/day (enteric coated) - preferred option as it has similar efficacy to MTX and is considered safe during pregnancy 1
• Leflunomide 20 mg/day - alternative with MTX-equivalent efficacy 1

Both agents have Level 1a evidence and Grade A recommendations from EULAR guidelines 1.

Glucocorticoid Considerations

Exercise extreme caution with glucocorticoids:

• While low-dose glucocorticoids are typically recommended as part of initial RA treatment strategy 1, they may contribute to peptic ulcer disease
• If disease activity is severe and glucocorticoids are necessary, use the lowest effective dose for the shortest duration (up to 6 months maximum) and taper as rapidly as clinically feasible 1
• Ensure adequate PPI coverage if glucocorticoids must be used 5

Treatment Monitoring and Adjustment

Ulcer Healing Timeline

• Reassess ulcer healing at 8 weeks with repeat endoscopy 2
• If partial response only, continue PPI therapy for another 8 weeks 2
• Most ulcers (87-90%) heal within this timeframe with PPI therapy 2, 4

RA Disease Activity Monitoring

• Monitor RA disease activity every 1-3 months as per standard treat-to-target approach 1, 6
• If no improvement by 3 months or target not reached by 6 months, adjust DMARD therapy 1
• The presence of gastric ulcer does NOT justify delaying aggressive RA treatment - comorbidities and safety issues should be considered when adjusting therapy, but treatment must still aim for remission or low disease activity 1

Escalation Strategy if Initial DMARD Fails

Without Poor Prognostic Factors

• Switch to another conventional synthetic DMARD strategy 1
• Consider triple therapy (hydroxychloroquine + sulfasalazine + leflunomide, avoiding MTX) 6

With Poor Prognostic Factors

(High disease activity, RF/ACPA positive, early joint damage)

Add biologic DMARD:

• Preferred agents: IL-6 inhibitors (tocilizumab, sarilumab) or abatacept - these can be used as monotherapy if conventional synthetic DMARDs cannot be continued 7
• Avoid TNF inhibitors if possible in patients with history of significant GI complications, though evidence is mixed 7, 8
• JAK inhibitors (tofacitinib, baricitinib, upadacitinib) are options but conditionally recommended in patients ≥65 years with cardiovascular risk factors 7

Critical Pitfalls to Avoid

1. Do not delay DMARD initiation - the gastric ulcer is not a reason to postpone RA treatment; it simply changes which DMARD to use 1

2. Do not assume asymptomatic = no ulcer - 53% of RA patients with gastric ulcers are asymptomatic, and "silent ulcers" can present with bleeding or perforation 3, 9

3. Do not restart NSAIDs until ulcer is completely healed and only with continuous PPI prophylaxis if absolutely necessary 2, 10

4. Do not use MTX until gastric ulcer is completely healed and GI function normalized 1

5. Smoking cessation is essential - 63% of RA patients with gastric ulcers are smokers versus 34% without ulcers 3

Long-term Management

Once ulcer heals and RA is controlled:

• Continue PPI prophylaxis indefinitely if NSAIDs or glucocorticoids are needed 10
• Consider switching to sulfasalazine + MTX combination once ulcer fully healed if better disease control needed
• Maintain treat-to-target approach with goal of remission or low disease activity 1, 6

The key principle is that comorbidities like gastric ulcer should influence drug selection but never delay aggressive RA treatment 1. Modern adherence to gastroprotection guidelines has reduced NSAID-induced GI events significantly 10.